Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthroid Sales Expected To Grow 12% For Year Following NDA Approval

Executive Summary

Abbott expects Synthroid growth of approximately 12% in 2002 following approval of the synthetic thyroid hormone replacement therapy's NDA
Advertisement

Related Content

Levothyroxine Bioequivalence Studies Need Thyroid-Free Baseline – Abbott
Levothyroxine Bioequivalence Studies Need Thyroid-Free Baseline – Abbott
King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
From The Quarterly Conference Calls
From The Quarterly Conference Calls
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
Advertisement
UsernamePublicRestriction

Register

PS040244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel